United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, November 19th. The stock was sold at an average price of $565.09, for a total value of $4,690,247.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $25,526,245.48. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
United Therapeutics Price Performance
UTHR stock opened at $559.10 on Friday. The business has a fifty day moving average price of $548.85 and a 200 day moving average price of $538.52. United Therapeutics Corporation has a fifty-two week low of $455.63 and a fifty-two week high of $614.23. The stock has a market capitalization of $23.81 billion, a price-to-earnings ratio of 21.10, a P/E/G ratio of 3.84 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). The business had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $7.16 EPS. On average, equities analysts expect that United Therapeutics Corporation will post 25.08 earnings per share for the current fiscal year.
United Therapeutics announced that its Board of Directors has approved a stock repurchase program on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its stock is undervalued.
Wall Street Analysts Forecast Growth
UTHR has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a report on Monday, October 26th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, November 9th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $697.00 to $725.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. TD Cowen increased their price objective on shares of United Therapeutics from $675.00 to $700.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $368.00 price objective on shares of United Therapeutics in a research report on Thursday, October 15th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $676.40.
Get Our Latest Stock Report on United Therapeutics
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of UTHR. BlackRock Inc. bought a new position in United Therapeutics in the 2nd quarter valued at $2,868,735,000. Janus Henderson Group PLC increased its stake in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $450,140,000. First Trust Advisors LP raised its position in shares of United Therapeutics by 40.4% during the third quarter. First Trust Advisors LP now owns 349,666 shares of the biotechnology company’s stock worth $189,480,000 after acquiring an additional 100,610 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of United Therapeutics during the second quarter worth $159,522,000. Institutional investors and hedge funds own 94.08% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Featured Articles
- Five stocks we like better than United Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
